Abstract: The present disclosure provides fused bicyclic heterocyclyl compounds and their derivatives of formula (I), which are therapeutically useful as CCR4 modulators. These compounds are useful in the treatment and/or prevention of diseases and/or disorders responsive to the modulation of CCR4 activity. Compounds of the present disclosure are especially useful for treating cancer and inflammatory diseases and disorders. The present disclosure also provides processes for preparation of the compounds and pharmaceutical formulations comprising at least one of the compounds of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.
| # | Name | Date |
|---|---|---|
| 1 | 202547117173-PRIORITY DOCUMENTS [26-11-2025(online)].pdf | 2025-11-26 |
| 2 | 202547117173-FORM 1 [26-11-2025(online)].pdf | 2025-11-26 |
| 3 | 202547117173-COMPLETE SPECIFICATION [26-11-2025(online)].pdf | 2025-11-26 |
| 4 | 202547117173-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [26-11-2025(online)].pdf | 2025-11-26 |
| 5 | 202547117173-FORM-5 [27-11-2025(online)].pdf | 2025-11-27 |
| 6 | 202547117173-FORM 18 [27-11-2025(online)].pdf | 2025-11-27 |
| 7 | 202547117173-FORM 3 [02-12-2025(online)].pdf | 2025-12-02 |
| 8 | 202547117173-Proof of Right [08-01-2026(online)].pdf | 2026-01-08 |